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Objectives: It is uncertain whether HIV-1 antiretroviral exposure and clinical response varies between males and
females or different race/ethnic groups. We describe ritonavir-enhanced atazanavir pharmacokinetics in relation
to virological failure, safety and tolerability in treatment-naive individuals to investigate potential differences.
Methods: Plasma samples were collected from participants in AIDS Clinical Trials Group Study A5202 for meas-
urement of antiretroviral concentrations. Individual estimates of apparent oral clearance of atazanavir (L/h) were
calculated from a one-compartment model and divided into tertiles as slow (,7), middle (7 to ,9; reference
group) and fast (≥9). Associations between atazanavir clearance and clinical outcomes were estimated with a
hazard ratio (HR) from Cox proportional hazards models. Interactions between atazanavir clearance and sex,
race/ethnicity and NRTIs were investigated for each of the outcomes.
Results: Among 786 participants, average atazanavir clearance was slower in females (n¼131) than males
(n¼655). Atazanavir clearance was associated with time to virological failure (P¼0.053) and this relationship
differed significantly by sex (P¼0.003). Females in the fast atazanavir clearance group had shorter time to
virological failure (HR 3.49; 95% CI 1.24–9.84) compared with the middle (reference) atazanavir clearance
group. Among males, the slow atazanavir clearance group had a higher risk of virological failure (HR 2.10;
95% CI 1.16–3.77).
Conclusions: Atazanavir clearance differed by sex. Females with fast clearance and males with slow clearance
had increased risk of virological failure.
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Introduction
Atazanavir is a potent once-daily PI and is recommended as a pre-
ferred active agent in combination antiretroviral regimens for
HIV-infected treatment-naive individuals. Atazanavir is one of
the most utilized PIs because of its efficacy, favourable tolerability,
durability and dosing convenience. The recommended and most
common dose of atazanavir in treatment-naive adults is 300 mg
plus 100 mg of ritonavir daily.1
Significant relationships between atazanavir plasma concen-
tration exposure, efficacy and safety have been demonstrated
but have also revealed marked interindividual variability in its
concentrations.2,3 The pharmacokinetics of atazanavir is charac-
terized by a rapid absorption phase that is dependent on gastro-
intestinal pH. It is moderately bound to a-1-acid glycoprotein
and albumin (89% and 86%, respectively) in plasma. Atazanavir
also undergoes extensive hepatic metabolism via CYP3A4/5,
with subsequent glucuronidation, and is a substrate for the drug
efflux transporter P-glycoprotein.4
Prior studies have investigated potential sources of atazanavir
variability to identify individual factors influencing its pharmaco-
kinetics and pharmacodynamics. Among these have been the
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following: genetic polymorphisms of CYP3A4/5, ABCB1 and ORM1;
albumin and a-1 glycoprotein acid concentrations; and antiretro-
virals and other concomitant medications.4 – 11 However, the
relationship of atazanavir exposure with patient-specific charac-
teristics, such as sex and race/ethnicity, has not been well
delineated.5,6,8,12 Moreover, pharmacodynamic disparities in anti-
retroviral exposure and clinical outcomes based on sex and race/
ethnicity are also ambiguous.13,14 This may be due to racial
and ethnic minorities and women being traditionally under-
represented in earlier phase studies when pharmacokinetic data
are most often collected, as well as in larger HIV therapeutics
clinical trials.15,16
AIDS Clinical Trials Group Study (ACTG) A5202 (NCT00118898)
randomly assigned treatment-naive participants to efavirenz- or
atazanavir/ritonavir-based combination antiretroviral therapy.
Plasma pharmacokinetic data were collected from the majority
of study participants at multiple timepoints, providing one of the
largest pharmacokinetic datasets for atazanavir in a clinical trial
setting. The pre-specified pharmacology objectives were to evalu-
ate the association of sex and self-reported race/ethnicity with
antiretroviral exposure, by comparing modelled antiretroviral
apparent oral clearance between men and women and between
Hispanics, black non-Hispanics (blacks) and white non-Hispanics
(whites); and to evaluate the association of modelled antiretroviral
clearance with virological failure, tolerability and safety endpoints.
Methods
Study design and participants
Study A5202 was a Phase IIIb, randomized, partially blinded comparison
study of four once-daily antiretroviral regimens in treatment-naive adults
(≥16 years of age). At screening, study participants were stratified by
HIV-1 RNA level (,100000 or ≥100000 copies/mL) and then randomized
1:1:1 :1 to open-label efavirenz (600 mg) or atazanavir/ritonavir (300/
100 mg), along with double-blinded placebo-controlled tenofovir
disoproxil fumarate (300 mg) plus emtricitabine (200 mg) or abacavir
(600 mg) plus lamivudine (300 mg). All research was conducted in accord-
ance with the Declaration of Helsinki. Human subject committees of all
sites approved the protocol and informed consent was obtained from all
participants.
The primary efficacy, safety and tolerability results have been previ-
ously reported.17 – 19 The primary efficacy outcome was time from ran-
domization to virological failure, defined as a confirmed plasma HIV-1
RNA level ≥1000 copies/mL at or after 16 weeks and before 24 weeks or
≥200 copies/mL at or after 24 weeks. The primary tolerability outcome
was assessed as time to first permanent modification of third drug (open-
label atazanavir/ritonavir or efavirenz), ignoring modification of NRTI and
temporary holds of antiretrovirals. The protocol originally defined the
tolerability endpoint as discontinuation of any active study drug, but this
endpoint was modified to just third drug after NRTI unblinding occurred
for participants of the high-screening viral load stratum based on a data
and safety monitoring board review.17,18 The primary safety endpoint was
time from treatment dispensation to the first development of grade 3 or 4
(i.e. severe or life-threatening) sign, symptom or laboratory abnormality
that was at least one grade higher than at baseline (excluding creatinine
kinase and bilirubin laboratory values).
Pharmacokinetic sampling and assays
In study ACTG A5202, blood samples for pharmacokinetic assessment
were collected with the goal of obtaining drug exposure estimates for all
study participants. A sparse sampling strategy was used to collect at least
three blood samples for population pharmacokinetic analyses. Antiretroviral
plasma concentrations assumed to have reached steady-state were
obtained over one to two visits during the first 24 weeks of therapy at
study weeks 4, 8, 16 or 24. For participants taking their atazanavir/
ritonavir-based regimen in the morning, two clinic visits (visits A and B)
were scheduled. At visit A, two blood samples were collected around an
observed dose with food (one sample collected before the dose and one
sample collected 3–4 h after the dose). At visit B, one sample was col-
lected 5–12 h after a regularly scheduled dose. The order of visit A and
visit B was flexible and could be combined at one visit if convenient for
the participant. Participants who took their regimen in the evening were
instructed to switch their dosing (both NRTIs and atazanavir/ritonavir) to
the morning for the 4 days prior to their scheduled clinic visit A. Two
samples were then collected around an observed dose as outlined
above. A separate visit B was also scheduled in order to collect a sample
5–15 h after a regularly scheduled evening dose.
Medication adherence training was provided to participants at entry.
Study participants’ adherence was assessed with an ACTG self-report
adherence questionnaire at weeks 8 and 24. Additionally, the dates and
times of the last three antiretroviral doses were recorded in the case report
forms, which were reviewed by the laboratory personnel of the University
at Buffalo Pharmacology Specialty Laboratory (UB PSL) to ensure adher-
ence prior to assaying atazanavir plasma concentrations.
Blood samples were stored on ice or isolated by centrifugation (800 g
for 10 min) within 90 min of collection. Plasma samples were then
aliquotted into polypropylene cryovials and stored at 2708C until ship-
ment to the UB PSL.20 Atazanavir concentrations were quantified using a
validated HPLC assay consistent with the Clinical Laboratory Improvement
Amendments, with the lower limit of quantification (LLQ) being 100 ng/mL.
Concentrations less than the LLQ were replaced with one-half of LLQ
(50 ng/mL), while samples with non-detectable concentrations were
excluded from the analysis. The accuracy of concentrations was evaluated
according to the ACTG and the NIH Clinical Pharmacology Quality
Assurance Program.
Pharmacokinetic analysis
For the atazanavir concentration–time data, population pharmacokinetic
analyses were performed with the computer program NONMEM VII
(ICON Development Solutions, Ellicott City, MD, USA). The first-order
conditional estimation with interaction method was used and one- and
two-compartment models were tested to find a structural model that
appropriately described the atazanavir concentration data without covari-
ates. Selection of the structural model was based on successful conver-
gence and goodness-of-fit plots (Figure S1, available as Supplementary
data at JAC Online). Similar to previous ritonavir-enhanced atazanavir
population pharmacokinetic studies, a one-compartment model with
first-order absorption and elimination was selected (minimizations were
unsuccessful with a two-compartment model).9 – 11,21 – 23 The model
was parameterized in terms of clearance, volume of distribution and an
absorption rate constant. The between-participant variability was
described using an exponential random effects model; a proportional
error model was used to describe residual variability. Individual Bayesian
estimates of apparent oral clearance (CL/F) for atazanavir were obtained
for each participant included in the pharmacokinetic model.
From the structural model, an allometric scaling model for body weight
on clearance (power of 0.75) and volume (power of 1) was used to inves-
tigate the covariate relationships of sex, tenofovir disoproxil fumarate
randomization, age and race/ethnicity upon atazanavir clearance.
Covariates were tested using a forward inclusion–backward elimination
method. Forward inclusion of a covariate required reduction in the
minimum objective function value (OFV) of≥3.84 (P,0.05, x2 distribution,
1 degree of freedom). Covariates included during the forward step were
individually eliminated and retained only if their removal increased the
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OFV by .10.83 (P,0.001, x2 distribution, 1 degree of freedom). Age (con-
tinuous) was centred on the median value and effects were included in
both linear and non-linear fits. Categorical covariates were tested in the
model as binary or ternary values using a proportional model.
Statistical analysis
Times to virological failure as well as primary tolerability and safety out-
comes were analysed as-treated (i.e. while prescribed atazanavir/ritonavir)
in relation to atazanavir CL/F. Individual area under the concentration–time
curves (AUCs) were not used because of possible dose–exposure non-
linearity in the prescribed dosage range (AUC¼dose/CL assumes dose–
exposure linearity).4 Atazanavir CL/F association analyses were restricted
to participants with estimated atazanavir CL/F values and those of white,
black or Hispanic race/ethnicity (categorized according to NIH ethnic and
racial definitions) due to low frequencies in other groups and as pre-
specified in the study protocol. Participant-specific estimated CL/F values
were evaluated by sex, race/ethnicity (three groups) and assigned NRTI
using a Satterthwaite t-test and 95% CI or one-way analysis of variance.
Time-to-event survival distributions were estimated by the Kaplan–
Meier method. Hazard ratios (HRs) were estimated with Cox proportional
hazards models stratified by screening HIV-1 RNA stratum and adjusted
for assigned NRTI and NRTI*RNA interaction term (denoted as ‘base
model’), due to the interaction results previously reported during an
interim analysis. During a planned data and safety monitoring board
interim analysis, a shorter time to virological failure was observed with
abacavir/lamivudine versus tenofovir disoproxil fumarate/emtricitabine
in the high HIV-1 RNA stratum, prompting unblinding of NRTI treatment
in this group of participants.17
It was pre-specified that atazanavir CL/F would be grouped into tertiles of
the overall distribution. A likelihood ratio test provided evidence that the rela-
tionship between atazanavir CL/F and the outcome was not linear (e.g.
numeric level 1, 2 or 3) and fit better as tertile categories (P¼0.011,
virological failure; P¼0.051, tolerability; and P¼0.25, safety). For consistency,
atazanavir CL/F was modelled as categories for each outcome. The middle
group was defined as the reference group (slow, ,7; middle, 7 to ,9; and
fast, ≥9 L/h). Previous pharmacokinetic modelling of HIV-infected adults
receiving a 300/100 mg dose of atazanavir/ritonavir have reported mean ata-
zanavir CL/F values ranging from 6.5 to 9.2 L/h, but most estimates have been
7 L/h.7,12,21–23 Therefore, the reference group was similar to the average
value reported in previous population pharmacokinetic studies.
Separate models evaluated interactions between atazanavir CL/F and
each of sex, race/ethnicity and assigned NRTI on the association with the
primary time to virological failure, tolerability and safety endpoints.
For each endpoint, the proportional hazards assumption was tested by
introducing an interaction term between atazanavir CL/F group and time
(discrete time for efficacy, continuous time for safety and tolerability); this
assumption was not violated (P≥0.49). Multivariable analyses were strati-
fied by screening HIV-1 RNA group and adjusted for NRTI, NRTI*RNA, sex,
race/ethnicity, age, CD4+ cell count and BMI at baseline and week 8 and
24 self-reported adherence over the 1 week prior to study visit (,100%
adherence at week 8 or 24 versus 100% at both visits). Sensitivity analyses
evaluated associations between atazanavir CL/F and the outcomes separ-
ately within each NRTI group. Pharmacokinetic objectives were specified
as secondary to study A5202 and the study was not formally powered
for these objectives. Analyses were conducted with two-sided a¼0.05
with no adjustments for multiple comparisons and were carried out in
SAS version 9.2 (SAS Institute, Cary, NC, USA).
Results
Study participants and pharmacokinetic collection
Of the 1857 eligible participants initially randomized in A5202,
926 (50%) were assigned to and initiated an atazanavir/ritonavir-
based therapy.18 There were no plasma atazanavir concentration
data for 105 (11%) participants who initiated atazanavir/ritonavir,
primarily because of premature discontinuation from the study or
study drug modification. Pharmacokinetic samples were available
from 821 participants receiving atazanavir/ritonavir; however, due
to dosing history discrepancies between the database and case
report forms, population pharmacokinetic analysis was restricted
to 815 (88% of 926) participants. Among these 815 individuals,
622 (76%) contributed at least three samples, 115 (14%) contrib-
uted two samples and 78 (10%) contributed one sample. Visits A
and B were combined on the same day for 189 (23% of 815) par-
ticipants. A total of 2195 atazanavir concentration samples were
analysed, with 48 (2%) samples below the LLQ (Figure S2).
Twenty-nine individuals from low frequency race/ethnicity groups
were excluded, leaving 786 participants for analyses (Table 1).
Table 1. Baseline characteristics for atazanavir/ritonavir subjects by
availability of plasma pharmacokinetic atazanavir data (restricted to










Assigned NRTIs, n (%)
TDF/FTC 389 (49) 55 (51) 0.780
ABC/3TC 397 (51) 53 (49)
Sex, n (%)
male 655 (83) 91 (84) 0.808
female 131 (17) 17 (16)
Age (years),
median (IQR)
39 (31–45) 38 (29–46) 0.544
Race/ethnicity, n (%)b
white, non-Hispanic 336 (43) 39 (36) 0.295
black, non-Hispanic 257 (33) 43 (40)
Hispanic 193 (25) 26 (24)
Screening HIV-1 RNA, n (%)




233 (81–336) 202 (69–332) 0.368
BMI (kg/m2),
median (IQR)
25 (22–28) 25 (22–28) 0.943
ATV, atazanavir; TDF/FTC, tenofovir disoproxil fumarate/emtricitabine;
ABC/3TC, abacavir/lamivudine.
aGroup differences for categorical variables were assessed with a x2 test.
Differences in continuous variables were assessed using a Mann–
Whitney test.
bEighteen Asian/Pacific Islanders, three Native American/Alaskan Natives,
seven subjects reporting more than one race and one subject with missing




From the one-compartment pharmacokinetic structural model,
the estimate of the mean population (relative standard error
expressed in percentage) first-order absorption rate constant
was 0.47 h21 (11), the estimated volume of distribution was
86.7 L (5) and the estimated CL/F of atazanavir was 7.86 L/h (2).
The estimated between-participant variability for CL/F expressed
as a coefficient of variation was 36% (8) and the estimated
residual variability was 46% (4). The estimated difference
between mean atazanavir CL/F rates was 0.74 L/h (95% CI
0.22–1.27) slower in females than in males [7.63 (standard devi-
ation 2.86) versus 8.37 (standard deviation 2.37) L/h; P¼0.006].
In the allometric scaled covariate model, sex was identified as
the only covariate that was significantly associated with clear-
ance, which was decreased in female participants by an average
of 14% compared with males (Table S1). For each of the atazana-
vir blood samples, the ritonavir concentration was also to be mea-
sured. However, of the 2156 ritonavir concentrations, 771 (36%)
were below the assay limit of detection, making it difficult to
develop a model with reliable parameter estimates of ritonavir
exposure. Among 734 participants of white, black or Hispanic
race/ethnicity and with detectable ritonavir concentrations avail-
able, the estimated mean plasma concentration was 672 (stand-
ard deviation 461) ng/mL among males (n¼613) and 832
(standard deviation 588) ng/mL among females (n¼121;
Satterthwaite t-test, P¼0.0001).
Participants randomized to abacavir/lamivudine had a mean
atazanavir CL/F that was slower by 0.51 L/h (95% CI 0.17–0.86)
compared with those receiving tenofovir disoproxil fumarate/emtri-
citabine: 7.99 (standard deviation 2.46) versus 8.51 (standard devi-
ation 2.45) L/h (P¼0.003). Among whites, blacks and Hispanics,
the estimated mean CL/F rates were 8.12 (standard deviation
2.33), 8.29 (standard deviation 2.70) and 8.42 (standard deviation
2.39) L/h, respectively, and did not differ significantly (P¼0.40).
Tenofovir disoproxil fumarate randomization and race/ethnicity
were not statistically significant in the allometric model.
Atazanavir oral clearance and time to virological failure
Overall, there were 106 (13.5%) protocol-defined virological
failure events among 786 participants included in this analysis
(Table 2). There were 44, 23 and 39 virological failures in the
fast, middle and slow atazanavir CL/F groups, respectively.
Atazanavir CL/F was moderately associated with time to viro-
logical failure (P¼0.053); fast versus middle atazanavir CL/F levels
had an estimated HR for virological failure of 1.81 (95% CI 1.08–
3.01) and slow versus middle atazanavir CL/F had an estimated
HR for virological failure of 1.76 (95% CI 1.04–2.96). However,
the association between atazanavir CL/F and virological failure
differed by sex (P¼0.003). Females in the fast atazanavir CL/F
group had the highest risk of virological failure, but the slow and
middle atazanavir CL/F groups were not demonstrably different
Table 2. Estimated association between atazanavir clearance level and the hazard of virological failure, tolerability and safety by sex, race/ethnicity and
NRTI arm (base modelsa)
Group
Comparisons by ATV clearance tertile
[number of events (VF/tolerability/safety)] Virological failure HR (95% CI) Tolerability HR (95% CI) Safety HR (95% CI)
Overallb P¼0.053 P¼0.128 P¼0.22
fast (44/72/95) versus middle (23/49/79) 1.81 (1.08–3.01) 1.30 (0.90–1.87) 1.06 (0.79–1.43)
slow (39/73/100) versus middle 1.76 (1.04–2.96) 1.45 (1.01–2.09) 1.28 (0.95–1.72)
Sexb P¼0.003 P¼0.070 P¼0.81
female fast (15/12/12) versus middle (5/4/13) 3.49 (1.24–9.84) 3.09 (1.00–9.59) 0.84 (0.38–1.84)
slow (8/12/28) versus middle 0.82 (0.26–2.54) 1.58 (0.51–4.91) 1.10 (0.57–2.14)
male fast (29/60/83) versus middle (18/45/66) 1.50 (0.82–2.71) 1.15 (0.78–1.70) 1.11 (0.80–1.53)
slow (31/61/72) versus middle 2.10 (1.16–3.77) 1.52 (1.03–2.24) 1.27 (0.91–1.77)
Race or ethnicityb P¼0.085 P¼0.51 P¼0.92
white fast (10/23/39) versus middle (9/27/40) 1.37 (0.55–3.39) 0.93 (0.53–1.62) 1.14 (0.73–1.78)
slow (14/25/43) versus middle 1.91 (0.82–4.45) 1.05 (0.61–1.80) 1.30 (0.85–2.01)
Hispanic fast (6/19/17) versus middle (8/10/15) 0.57 (0.20–1.67) 1.44 (0.67–3.10) 0.79 (0.39–1.58)
slow (4/17/16) versus middle 0.53 (0.16–1.79) 1.85 (0.85–4.06) 1.04 (0.51–2.10)
black fast (28/30/39) versus middle (6/12/24) 3.38 (1.38–8.25) 1.84 (0.94–3.60) 1.16 (0.70–1.93)
slow (21/31/41) versus middle 2.67 (1.07–6.67) 1.89 (0.97–3.69) 1.34 (0.81–2.23)
NRTIsb P¼0.58 P¼0.121 P¼0.31
ABC/3TC fast (23/38/49) versus middle (15/29/42) 1.83 (0.95–3.54) 1.47 (0.91–2.39) 1.32 (0.88–2.00)
slow (21/36/57) versus middle 1.47 (0.75–2.88) 1.19 (0.73–1.94) 1.41 (0.94–2.10)
TDF/FTC fast (21/34/46) versus middle (8/20/37) 1.86 (0.82–4.22) 1.16 (0.67–2.02) 0.83 (0.54–1.28)
slow (18/37/43) versus middle 2.28 (0.99–5.28) 1.84 (1.07–3.18) 1.13 (0.73–1.76)
ABC/3TC, abacavir/lamivudine; ATV, atazanavir; TDF/FTC, tenofovir disoproxil fumarate/emtricitabine; VF, virological failure.
aEach base model was stratified by screening HIV-1 RNA stratum (, or ≥105 copies/mL), and also adjusted for NRTI and NRTI by screening RNA
interaction.
bInteraction P value between group and atazanavir clearance tertile.
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(Figure 1). In contrast, among males, the slow atazanavir CL/F
group had a higher risk of virological failure and there was not a sig-
nificant difference between fast and middle atazanavir CL/F groups.
The association between atazanavir CL/F and time to viro-
logical failure did not differ significantly by NRTI (P¼0.58;
Table 2). The atazanavir CL/F-by-race/ethnicity interaction term
yielded P¼0.085 (Table 2); black participants with fast or
slow atazanavir CL/F each had higher rates of virological failure
compared with black non-Hispanic participants with middle
atazanavir CL/F (Figure S3). The race/ethnicity interaction was
not significant after adjustment for the sex-by-CL/F interaction
(P¼0.19) and the CL/F-by-sex interaction remained significant in
this analysis (P¼0.007, data not shown). The association between
atazanavir CL/F and time to virological failure did not significantly
differ by HIV-1 RNA screening stratum, baseline CD4+ cell count,
age, BMI or self-reported week 8 and 24 adherence (P≥0.47, data
not shown). Exploratory three-way interactions between atazana-
vir CL/F–sex–race/ethnicity and atazanavir CL/F–sex–NRTI were
not detected (P¼0.94 and P¼0.60, respectively).
In a multivariable model, the estimated association of ataza-
navir CL/F by sex with time to virological failure was similar
to the base model results and remained significant but with
slightly attenuated results (P¼0.003; Table 3). From the same
multivariable model, the time to virological failure was shorter
for females compared with males within the fast atazanavir
CL/F group (HR 4.57; 95% CI 2.33–8.95), but was not demonstrably
different within the middle atazanavir CL/F group (HR 2.10; 95% CI
Faster (≥9 L/h) (29 events)
Middle (7 to <9 L/h) (18 events)
Slower (<7 L/h) (31 events)
Faster (≥9 L/h)
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Middle (7 to <9 L/h) (5 events)
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0 24 48 72 96 120 144 168 192 216
Figure 1. Kaplan–Meier plots of time to virological failure by atazanavir clearance groups for males and females. Sex-by-atazanavir clearance
interaction P¼0.003. ATV/r, atazanavir/ritonavir.
Table 3. Estimated association between atazanavir clearance levels on










Female fast versus middle 2.97 (1.02–8.61) 3.14 (1.01–9.81)
slow versus middle 0.72 (0.23–2.26) 1.63 (0.52–5.08)
Male fast versus middle 1.36 (0.74–2.51) 1.15 (0.78–1.70)
slow versus middle 1.98 (1.09–3.59) 1.43 (0.97–2.11)
ATV, atazanavir.
aStratified by HIV-1 RNA screening stratum and adjusted for NRTI,
NRTI-by-HIV-1 RNA stratum interaction, race/ethnicity, age, baseline
CD4+ cell count, BMI and week 8 and 24 adherence.
bSex-by-atazanavir clearance interaction P¼0.003 for virological failure.
cSex-by-atazanavir clearance interaction P¼0.094 for tolerability.
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0.75–5.91) or slower CL/F group (HR 0.76; 95% CI 0.34–1.73).
Results were similar in an intention-to-treat sensitivity analysis of
atazanavir CL/F and virological failure (data not shown).
Atazanavir oral clearance and tolerability
Among fast, middle and slow atazanavir CL/F groups, 72, 49 and
73 participants modified atazanavir/ritonavir treatment, respect-
ively. Time to atazanavir/ritonavir modification did not differ
substantially by atazanavir CL/F group [fast versus middle ataza-
navir clearance HR 1.30 (95% CI 0.90 –1.87) and slow versus
middle atazanavir clearance HR 1.45 (95% CI 1.01 –2.09);
P¼0.128]. The interaction between sex and the CL/F level yielded
P¼0.070 (Table 2); multivariable model results were similar
(Table 3). There was no significant interaction by race/ethnicity
or NRTI group (Table 2).
Among females with fast atazanavir CL/F, 68% (26/38)
completed atazanavir/ritonavir treatment, compared with 86%
(25/29) and 81% (52/64) among females with middle and slow
atazanavir CL/F, respectively. Among males, the proportions com-
pleting atazanavir/ritonavir treatment were 76% (189/249), 79%
(165/210) and 69% (135/196) among those with fast, middle and
slow atazanavir CL/F, respectively (Figure 2). The most commonly
provided reason for atazanavir/ritonavir modification was non-
compliance with study medications or visits among females
(8%) and males (10%). Eighteen percent (7/38) of females cate-
gorized as having a fast atazanavir CL/F were recorded to have
discontinued atazanavir for non-compliance compared with 7%
(2/29) of those with middle and 3% (2/64) with slow CL/F.
Among males with slow atazanavir CL/F, 14% (28/196) reported
non-compliance as a reason for atazanavir modification, compared
with 9% of males with either middle (18/210) or fast (22/249) ata-
zanavir CL/F. The reasons for atazanavir/ritonavir modification are
summarized in Table S2.
Atazanavir oral clearance and safety events
A total of 274 grade 3 or 4 safety events were reported: 95, 79 and
100 events in the fast, middle and slow atazanavir CL/F groups,
respectively. There was not a significant association between
atazanavir CL/F group and time to safety event [fast versus middle
atazanavir CL/F HR 1.06 (95% CI 0.79–1.43) and slow versus
middle atazanavir CL/F HR 1.28 (95% CI 0.95–1.72); P¼0.22].
There were no significant interactions between atazanavir CL/F
and sex (Figure 3), race/ethnicity or NRTI (Table 2).
Faster (≥9 L/h) (60 events)
Middle (7 to <9 L/h) (45 events)
Slower (<7 L/h) (61 events)
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Figure 2. Kaplan–Meier plots of time to atazanavir/ritonavir treatment modification by atazanavir clearance groups for males and females.
Sex-by-atazanavir clearance interaction P¼0.07. ATV/r, atazanavir/ritonavir.
Atazanavir pharmacokinetics and outcomes
3305
JAC
Post hoc sensitivity analyses among LLQ samples
Unlike standard pharmacokinetic studies with intensive sam-
pling, the sparse pharmacokinetic study design in A5202
depended on the participants’ own disclosure of adherence to
study medications. To further assess possible undisclosed non-
adherence, the primary results were also assessed through
post hoc sensitivity analyses focusing on participants with an
atazanavir concentration below the LLQ by (i) excluding study
participants with atazanavir concentration(s) below the LLQ
prior to 20 h post-dose on visits in which there was no directly
observed therapy dose (n¼9) and (ii) excluding study partici-
pants with atazanavir concentration(s) below the LLQ at any
time post-dose (n¼44).
In the first analysis (i), it was hypothesized that participants
with an atazanavir concentration below the LLQ at timepoints
before 20 h post-dose were the most likely to represent non-
adherence based on the elimination half-life of atazanavir/ritona-
vir (8 h). With their exclusion, the atazanavir CL/F-by-sex inter-
action remained significant for time to virological failure [among
women, fast versus middle atazanavir CL/F HR 3.37 (95% CI 1.18–
9.56); among men, slow versus middle atazanavir CL/F HR 1.93
(95% CI 1.06–3.52); P¼0.004] and time to tolerability [among
women, fast versus middle atazanavir CL/F HR 2.95 (95% CI
0.94–9.28); among men, slow versus middle atazanavir CL/F HR
1.50 (95% CI 1.01–2.21); P¼0.085].
Furthermore, excluding all participants with an LLQ value (ii),
the atazanavir CL/F-by-sex interaction remained significant with
respect to virological failure. For time to virological failure
among women, fast versus middle atazanavir CL/F HR was 2.07
(95% CI 0.66–6.48); among men, slow versus middle atazanavir
CL/F HR was 1.97 (95% CI 1.06–3.64); P¼0.012. For time to toler-
ability among women, fast versus middle atazanavir CL/F HR was
2.06 (95% CI 0.60–7.04); among men, slow versus middle ataza-
navir CL/F HR was 1.54 (95% CI 1.04–2.30); P¼0.23. Results by
race/ethnicity and NRTI treatments for time-to-event outcomes
were similar to the original analyses (data not shown).
Discussion
In this report, we used atazanavir plasma concentration data
collected from ACTG study A5202 to compare atazanavir pharma-
cokinetics and time to clinical events by sex, race/ethnicity and
assigned NRTI arm. The clearance of atazanavir was reduced in
females compared with males after accounting for differences
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Faster (≥9 L/h) (83 events)
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Figure 3. Kaplan–Meier plots of time to safety event by atazanavir clearance groups for males and females. Sex-by-atazanavir clearance interaction
P¼0.81. ATV/r, atazanavir/ritonavir; NA, not applicable.
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principles, differences in atazanavir clearance were not apparent
by randomized NRTI arm or race/ethnicity.
Sex-related variability of PI plasma concentrations has been
previously reported for some PIs, including atazanavir/ritonavir.
However, the pharmacodynamics and clinical implications
had not been determined. According to previous studies, the
mean clearance of atazanavir is reduced by 10% –30% in
females.6,12,23 Here, female study participants in A5202 had
8.8% lower mean individual Bayesian predicted clearances com-
pared with males and an overall 14% lower clearance in the
allometric adjusted model.
The mechanisms behind sex-based variability in atazanavir
oral clearance have not been fully elucidated, but several potential
factors do vary by sex.24 Gastric emptying time is generally slower
in females than males, presumably due to hormonal effects
from oestrogen and progesterone, which may allow for greater
atazanavir absorption and bioavailability.25,26 Ritonavir exposure
in females is also typically higher compared with males, which
was consistent with A5202 participants who had detectable
ritonavir concentrations.27,28 This lends support to the notion
that variability in ritonavir exposure is relevant to sex-related
differences of PI pharmacokinetics. Unfortunately, we were
unable to explicitly test this in our model due to a significant
amount of missing and undetectable ritonavir concentrations.
Whether the true underlying factor in atazanavir exposure
variability between males and females is due to direct differences
in atazanavir metabolism and disposition or is more indirectly
linked to sex-related ritonavir pharmacokinetic differences
requires further investigation.
There was also a race/ethnicity imbalance between females
and males. Among females (males), 18% (48%) were white,
50% (29%) were black and 32% (23%) were Hispanic. According
to 2011 data among adult and adolescents diagnosed with HIV
infection, these reflect an over-representation of Hispanic females
and white males by 15%–18% and an under-representation of
black males and females by 13%.29 In Figure S4, the patterns of
increased virological failure among females with fast atazanavir
clearance and males with slow clearance remain descriptively
apparent for white and black participants (there was no evidence
of an interaction between atazanavir clearance, sex and race/eth-
nicity; P¼0.9). These patterns appear most pronounced among
blacks, particularly black females, making it difficult to exclude
race/ethnicity as a key factor in the observed results.
Despite the sex-related differences of atazanavir clearance, the
interpretation of virological failure and tolerability outcomes by
atazanavir clearance and sex was not straightforward due to dis-
cordant results among males and females. For males with slow
atazanavir clearance, there was an association with worsened
virological failure and tolerability outcomes. For females, having
fast atazanavir clearance was associated with faster time to viro-
logical failure and tolerability events. This pattern of tolerability in
females may have been due in part to discontinuation of atazana-
vir/ritonavir occurring after virological failure. Among females who
had an intolerability event, 6/12 with fast atazanavir clearance
modified treatment after virological failure was determined,
whereas most atazanavir modifications in the middle (3/4) and
slow (9/12) clearance groups occurred without virological failure.
Intuitively, one could assume the overall slower atazanavir
clearance among females could lead to either better virological
response because of higher exposure or, if toxic levels were
reached, to worse virological response from intolerability leading
to non-adherence of any or all components of the antiretroviral
regimen. Smith et al.30 found that in A5202, females assigned
to atazanavir/ritonavir had a higher risk of virological failure
than men assigned to atazanavir/ritonavir, while risks of intoler-
ability and safety events were not different by sex, and neither
was self-reported adherence. Here, we show that the risk of viro-
logical failure and intolerability appears to depend on the degree
of atazanavir clearance differently for males and females.
Females with fast atazanavir clearance were at the highest risk
of virological failure, presumably due to low drug exposure, but
males with fast atazanavir clearance had reasonable efficacy.
The reasons for intolerability from males with a slower clear-
ance of atazanavir suggest that these individuals had suboptimal
adherence to study medications and procedures (Table S2).
This may have been an important factor leading to their overall
higher rates of virological failure. Their increased exposure to ata-
zanavir indicates adequate periclinic visit medication adherence.
However, underlying intolerability to study treatments may have
been a source of undetected sporadic non-adherence over the
course of the study. Therefore, a potential limitation of this
study is the nature of the sparse pharmacokinetic sampling
design and modelling, which required assumptions of adherence
to study medications leading up to plasma concentration collec-
tions for pharmacokinetic measures. Adherence is a dynamic pro-
cess, and thus this assumption may not be entirely accurate
across our study population. Performing traditional intensive
pharmacokinetic sampling around a directly observed dose in all
study participants, however, was not an economically feasible
option.
Approximately 85% of participants included in this analysis
indicated 100% adherence to all reported antiretrovirals over
1 week prior to the study visit at weeks 8 and 24. The possibility
of unreported non-adherence was explored through sensitivity
analyses by excluding participants with atazanavir concentrations
that were below the atazanavir assay limit of quantification.
Results among women were attenuated for virological failure
and tolerability outcomes by assuming LLQ samples were
associated with non-adherence rather than rapid atazanavir
clearance; however, the overall interaction of sex remained
significant.
Our study did not intend to investigate every potential source
of variability in atazanavir pharmacokinetics, but rather pre-
selected specific patient-level factors. Therefore, differences
in body composition, genetics, underlying pathophysiological
processes and other concomitant medications (e.g. gastric acid
reducers, CYP3A inhibitors and inducers) may also be important
to consider but were not addressed here. Additionally, we evalu-
ated the pharmacokinetics of one antiretroviral drug, atazanavir/
ritonavir, while in reality the virological response is more complex
due to the presence of NRTI agents in a combination regimen.
Plasma concentrations of the other antiretrovirals were measured
in A5202 and are planned to be evaluated in future analyses.
A major strength of this study was the large sample size com-
pared with other previous studies and therefore a greater ability to
detect differences in atazanavir pharmacokinetics between
groups. With plasma concentration data collected from .130
women, ACTG study A5202 represents the largest US-based ran-
domized study to compare atazanavir exposure in HIV-infected
women. Comparison of atazanavir exposure and outcomes by
Atazanavir pharmacokinetics and outcomes
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sex were secondary outcomes and enrolment into A5202 was not
stratified by sex. The male-to-female study participant ratio in
A5202 was imbalanced (5:1) but reflected recently reported esti-
mates of HIV infection diagnoses among adults and adolescents
in the USA (4:1).29
In summary, A5202 used a sparse pharmacokinetic sampling
study design that allowed for the collection and analysis of the
majority of participants enrolled and randomized to atazanavir/
ritonavir. While there has been a lack of consistency in the under-
standing of sex- and race/ethnicity-related pharmacokinetic and
pharmacodynamic variability of atazanavir/ritonavir, we have
identified sex as an important factor in atazanavir/ritonavir
pharmacokinetics and treatment outcomes.
Acknowledgements
These data were presented in part as abstracts at the Nineteenth
Conference on Retroviruses and Opportunistic Infections, Seattle, WA,
2012 (Abstract 612) and at the International AIDS Conference,
Washington, DC, 2012 (Abstract TUPDB0101).
We would like to thank the staff of the University at Buffalo ACTG
Pharmacology Specialty Laboratory, Dr Susan Rosenkranz, PhD and Ms
Darlene Lu, MS from the Statistical and Data Analysis Center (Harvard
School of Public Health, Boston, MA, USA) of the AIDS Clinical Trials Group,
as well as Ms Laurie Myers, MS and Mr Anthony Bloom, BA from Frontier
Science & Technology Research Foundation, Inc. (Amherst, NY, USA)
for their assistance in data management. We would also like to
thank Abbott Laboratories, Bristol-Myers Squibb, Gilead Inc. and
GlaxoSmithKline for providing antiretroviral agents used in this trial.
Finally, we would like to especially thank the investigators, study
coordinators and study participants of ACTG A5202.
Other investigators and contributors included the
following
Hector H. Bolivar, MD and Sandra Navarro, MD—University of Miami
(Site 901) CTU Grant #AI069477, ACTG Grant #AI27675, CFAR Grant
#AI073961; Susan L. Koletar, MD and Diane Gochnour, RN—Ohio State
University (Site 2301) CTU Grant #AI069474; Edward Seefried, RN and
Julie Hoffman, RN—University of California, San Diego (Site 701) CTU
Grant #AI69432; Judith Feinberg, MD and Michelle Saemann, RN—
University of Cincinnati (Site 2401) CTU Grant #AI069513; Kristine
Patterson, MD, Donna Pittard, RN and David Currin, RN—University of
North Carolina (Site 3201) CTU Grant #AI69423, CFAR Grant #AI50410,
GCRC Grant #RR00046 and Grant #RR025747; Kerry Upton, RN, BSN and
Michael Saag, MD—University of Alabama (Site 5801) CTU Grant #U01
AI069452, CCTS Grant #1UL1 RR025777-01; Graham Ray and Steven
Johnson—University of Colorado Health Sciences Center (Site 6101) CTU
Grant #AI69450, Grant #AI054907, Grant #RR00051; Bartolo Santos, RN
and Connie A. Funk, RN, MPH—University of Southern California (Site
1201) CTU Grant #5U01 AI069428; Michael Morgan, FNP and Brenda
Jackson, RN—Vanderbilt Therapeutics CRS (Site 3652) CTU Grant
#AI069439; Pablo Tebas, MD and Aleshia Thomas, RN—University of
Pennsylvania, subunit of Children’s Hospital of Philadelphia (Site 6201)
CTU Grant #U01 AI069467-03, CFAR Grant #5P30 AI045008-10; Ge-Youl
Kim, RN, BSN and Michael K. Klebert, PhD, RN, ANP-BC—Washington
University (Site 2101) CTU Grant #AI069495; Jorge L. Santana and
Santiago Marrero—University of Puerto Rico (Site 5401) CTU Grant
#5U01 AI069415-03; Jane Norris, PA-C and Sandra Valle, PA-C—Stanford
University (Site 501) CTU Grant #AI69556; Gary Matthew Cox, MD and
Martha Silberman, RN—Duke University Medical Center (Site 1601) CTU
Grant #5U01 AI069484-02; Sadia Shaik and Ruben Lopez—
Harbor-University of California, Los Angeles Medical Center (Site 603)
CTU Grant #AI069424; Margie Vasquez, RN and Demetre Daskalakis,
MD—New York University/NYC HHC at Bellevue Hospital Center (Site 401)
CTU Grant #AI069532; Christina Megill, RPA-C and Todd Stroberg, RN—
Cornell Chelsea (Site 7804) CTU Grant #AI69419, CSTC Grant
#RR024996; Jessica Shore, BSN and Babafemi Taiwo, MBBS—
Northwestern University CRS (Site 2701) CTU Grant #AI069471; Mitchell
Goldman, MD and Molly Boston, RN—Indiana University (Site 2601) CTU
Grant #UO1 AI025859; Dr Jeffrey Lennox and Dr Carlos del Rio—Ponce
de Leon Center (A5802) CTU Grant #5U01 AI069418, CFAR Grant #P30
AI050409; Timothy W. Lane, MD and Kim Epperson, RN—Moses H. Cone
Memorial Hospital (Site 3203) CTU Grant #1U01 A1069423-01; Annie
Luetkemeyer, MD and Mary Payne, RN—University of California, San
Francisco (Site 801) CTU Grant #1U01 AI069502-01; Barbara Gripshover,
MD and Dawn Antosh, RN—Case Western Reserve University (Site 2501)
CTU Grant #AI69501; Jane Reid, RN, MS, APN-BC and Mary Adams, RN,
MPh—University of Rochester (Site 1101) CTU Grant #U01 AI069511,
GCRC Grant #UL1 RR024160; Sheryl S. Storey, PA-C and Shelia
B. Dunaway, MD—University of Washington (Site 1401) CTU Grant
#AI069434; Joel Gallant, MD and Ilene Wiggins, RN—Johns Hopkins
University (Site 201) CTU Grant #AI69465; Kimberly Y. Smith, MD MPH
and Joan A. Swiatek, RN, APN—Rush University Medical Center (Site
2702) CTU Grant #5U01 AI069471; Joseph Timpone, MD and Princy
Kumar, MD—Georgetown University (Site 1008) CTU Grant #1U01
AI069494-01; Ardis Moe, MD and Maria Palmer PA-C—University of
California, Los Angeles Care Center (Site 601) CTU Grant #AI069424; Jon
Gothing, RN, BSN, ACRN and Joanne Delaney, RN, BSN—Brigham and
Women’s Hospital, Boston, MA (Site 107) CTU Grant #AI069472; Kim
Whitely, RN and Ann Marie Anderson, RN—Metro Health Center (Site
2503) CTU Grant #AI069501; Scott M. Hammer and Michael T. Yin—HIV
Prevention & Treatment (Columbia University) (Site 30329) CTU Grant
#5U01 AI069470, Grant #1UL1 RR024156; Mamta Jain, MD and Tianna
Petersen, MS—UT Southwestern Medical Center at Dallas (Site 3751) CTU
Grant #3U01 AI046376 05S4; Roberto Corales, DO and Christine Hurley,
RN—AIDS Community Health Center (Site 1108) CTU Grant #U01
AI069511, GCRC Grant #UL1 RR024160; Keith Henry, MD and Bette
Bordenave, RN—Hennepin County Medical Center (Site 1502) Grant #N01
AI72626; Amanda Youmans, NP and Mary Albrecht, MD—Beth Israel
Deaconess (Partners/Harvard) CRS (Site 103) CTU Grant #UOI
A106947203; Richard B. Pollard, MD and Abimbola Olusanya, NP—
University of California, Davis Medical Center (Site 3851) Grant
#AI38858; Paul R. Skolnik, MD and Betsy Adams, RN—Boston Medical
Center CRS (Site 104) CTU Grant #AI069472; Karen T. Tashima and Helen
Patterson—Miriam Hospital-Brown University (Partners/Harvard) (Site
2951) CTU Grant #1U01 AI069472-01; Michelle Ukwu and Lauren
Rogers—Peabody Health Center (Site 31443) CTU Grant #AI069471;
Henry H. Balfour, Jr, MD and Kathy A. Fox, RN, MBA—University of
Minnesota (Site 1501) CTU Grant #AI27661; Susan Swindells, MBBS and
Frances Van Meter, APRN—University of Nebraska Medical Center (Site
1505) CTU Grant #AI27661; University of Hawaii (Site 5201) CTU Grant
#AI34853; Gregory Robbins, MD and Nicole Burgett-Yandow, RN, BSN—
Massachusetts General Hospital from the Partners/Harvard/BMC ACTU
(Site 101) CTU Grant #1U01 AI069472-01; Dr Charles E. Davis, Jr and
Colleen Boyce, RN—IHV Baltimore Treatment CRS (Site 4651) CTU Grant
#5U01 AI069447 03; William A. O’Brien, MD and Gerianne Casey—
University of Texas Medical Branch (Site 6301) CTU Grant #AI032782; Dr
Gene D. Morse, PharmD and Dr Chiu-Bin Hsaio, MD—SUNY-Buffalo (Site
1102) CTU Grant #5U01 A1027658; San Mateo County AIDS Program
(Site 505) CTU Grant #AI27666; Jeffrey L. Meier and Jack T. Stapleton—
University of Iowa Healthcare (Site 1504) NIAID Grant #AI27661, Grant
#AI58740; Donna Mildvan, MD and Manuel Revuelta, MD—Beth Israel
Medical Center ACTU (Site 2851) CTU Grant #AI46370; David Currin,
RN—Wake County HHS (Site 30076) CTU Grant #AI25868; Wafaa El Sadr,
Venuto et al.
3308
MD, MPH, MPA and Avelino Loquere, RN—Harlem ACTG CRS (Site 31483)
CTU Grant #5U01 AI069470-03; Nyef El-Daher, MD and Tina Johnson,
RN—McCree McCuller Wellness Center (Site 1107) CTU Grant #U01
AI069511, GCRC Grant #UL1 RR024160; Robert Gross MD, MSCE and
Kathyrn Maffei, RN, BSN—University of Pennsylvania Health (Site 6206)
CTU Grant #1U01 AI69467-01; Valery Hughes, FNP and Glenn Sturge,
BS—Cornell Uptown (Site 7803) CTU Grant #1U01 AI069419-01;
Deborah McMahon, MD and Barbara Rutecki, CRNP, MPH—University of
Pittsburgh (Site 1001) CTU Grant #1UO1 AI069494-01; Michael
Wulfsohn, MD PhD, Andrew Cheng, MD PhD and Norbert Bischofberger
PhD—Gilead Sciences; and Lynn Dix, PhD and Qiming Liao, PhD—
GlaxoSmithKline, Inc.
Funding
This research was supported by grants from the National Institute of
Allergy and Infectious Diseases, National Institutes of Health (AI38858,
to the ACTG Central Group; AI68636, to the ACTG Network; AI68634
and AI38855, to the ACTG Statistical and Data Analysis Center;
U01AI068636 and UM1AI106701-01 to the University at Buffalo
Pharmacology Specialty Laboratory; AI069434, to the University of
Washington; AI069477, to the University of Miami). Additional support
from the General Clinical Research Center units funded by the National
Center for Research Resources and P30 AI50410, to the University
of North Carolina at Chapel Hill CFAR. Also, support from the NIH
Experimental Therapeutics in Neurological Disorders grant T32
NS007338 at the University of Rochester.
Transparency declarations
K. M. received research support from Gilead through the University of North
Carolina at Chapel Hill. E. S. D. received research grant support from Abbott,
Bristol-Myers Squibb, Gilead, Merck and ViiV, and is a consultant/advisor for
Abbvie, Bristol-Myers Squibb, Gilead, Janssen, Merck & Company and
ViiV. P. E. S. serves as a consultant or Scientific Advisory Board member
for Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck &
Company and Janssen, and has received grant support for research from
Bristol-Myers Squibb, Gilead and GlaxoSmithKline. M. F. has current
research support from Merck & Company and Pfizer, and previous research
support from Abbott Laboratories and GlaxoSmithKline. A. C. C. has current
research support from Merck & Company and previous research support
from Boehringer-Ingelheim, Gilead Sciences, Schering-Plough and
Tibotec-Virco, and was a member of a DSMB for a Merck-sponsored
study. A. C. C. and immediate family members previously owned stock in
Abbott Laboratories, Bristol-Myers Squibb, Johnson & Johnson and Pfizer.
K. Y. S. changed affiliations from Rush University Medical Center, Chicago,
IL, USA to ViiV Healthcare after the completion of the study, analysis and
writing of this article. K. Y. S. was a consultant/advisor for Abbott,
Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Janssen, Merck &
Company and ViiV. C. T. is a member of a Data Monitoring Committee
for Tibotec. All other authors: none to declare.
Supplementary data
Figures S1 to S4, Table S1 and Table S2 are available as Supplementary
data at JAC Online (http://jac.oxfordjournals.org/).
References
1 Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines
for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
Adolescents. Department of Health and Human Services. http://aidsinfo.
nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.
2 Bertz RJ, Persson A, Chung E et al. Pharmacokinetics and pharmaco-
dynamics of atazanavir-containing antiretroviral regimens, with or with-
out ritonavir, in patients who are HIV-positive and treatment-naı̈ve.
Pharmacotherapy 2013; 33: 284–94.
3 Fabbiani M, Di Giambenedetto S, Ragazzoni E et al. Mid-dosing interval
concentration of atazanavir and virological outcome in patients treated for
HIV-1 infection. HIV Med 2010; 11: 326–33.
4 Reyataz (Package Insert). Princeton, NJ: Bristol-Myers Squibb, 2013.
5 Anderson PL, Aquilante CL, Gardner EM et al. Atazanavir pharmacokin-
etics in genetically determined CYP3A5 expressors versus non-expressors.
J Antimicrob Chemother 2009; 64: 1071–9.
6 Kile DA, MaWhinney S, Aquilante CL et al. A population pharmacokinetic-
pharmacogenetic analysis of atazanavir. AIDS Res Hum Retroviruses 2012;
28: 1227–34.
7 Savic RM, Barrail-Tran A, Duval X et al. Effect of adherence as measured
by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharma-
cokinetics in treatment-naı̈ve HIV-infected patients. Clin Pharmacol Ther
2012; 92: 575–83.
8 Rodriguez Novoa S, Barreiro P, Rendon A et al. Plasma levels of atazana-
vir and the risk of hyperbilirubinemia are predicted by the 3435CT
polymorphism at the multidrug resistance gene 1. Clin Infect Dis 2006;
42: 291–5.
9 Barrail-Tran A, Mentre F, Cosson C et al. Influence of a-1 glycoprotein
acid concentrations and variants on atazanavir pharmacokinetics in
HIV-infected patients included in the ANRS 107 trial. Antimicrob Agents
Chemother 2010; 54: 614–9.
10 Taburet AM, Piketty C, Chazallon C et al. Interactions between atazanavir-
ritonavir and tenofovir in heavily pretreated human immunodeficiency
virus-infected patients. Antimicrob Agents Chemother 2004; 48: 2091–6.
11 Dailly E, Tribut O, Tattevin P et al. Influence of tenofovir, nevirapine and
efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-
infected patients. Eur J Clin Pharmacol 2006; 62: 523–6.
12 von Hentig N, Babacan E, Lennemann T et al. The steady-state
pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpati-
ents is not affected by gender-related co-factors. J Antimicrob Chemother
2008; 62: 579–82.
13 Floridia M, Giuliano M, Palmisano L et al. Gender differences in the
treatment of HIV infection. Pharmacol Res 2008; 58: 173–82.
14 Rotger M, Csajka C, Telenti A. Genetic, ethnic, and gender differences in
the pharmacokinetics of antiretroviral agents. Curr HIV/AIDS Rep 2006; 3:
118–25.
15 Pinnow E, Sharma P, Parekh A et al. Increasing participation of women
in early phase clinical trials approved by the FDA. Womens Health Issues
2009; 19: 89–93.
16 Gifford AL, Cunningham WE, Heslin KC et al. Participation in research
and access to experimental treatments by HIV-infected patients. N Engl
J Med 2002; 346: 1373–82.
17 Sax PE, Tierney C, Collier AC et al. Abacavir-lamivudine versus tenofovir-
emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361: 2230–40.
18 Daar ES, Tierney C, Fischl MA et al. Atazanavir plus ritonavir or efavirenz
as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med
2011; 154: 445–56.
19 Sax PE, Tierney C, Collier AC et al. Abacavir/lamivudine versus tenofovir
DF/emtricitabine as part of combination regimens for initial treatment of
HIV: final results. J Infect Dis 2011; 204: 1191–201.
20 Keil K, Hochreitter J, DiFrancesco R et al. Integration of atazanavir into
an existing liquid chromatography UV method for protease inhibitors:
validation and application. Ther Drug Monit 2007; 29: 103–9.
Atazanavir pharmacokinetics and outcomes
3309
JAC
21 Rekic D, Clewe O, Roshammar D et al. Bilirubin—a potential marker of
drug exposure in atazanavir-based antiretroviral therapy. AAPS J 2011; 13:
598–605.
22 Schipani A, Dickinson L, Boffito M et al. Simultaneous population phar-
macokinetic modelling of atazanavir and ritonavir in HIV-infected adults
and assessment of different dose reduction strategies. J Acquir Immune
Defic Syndr 2013; 62: 60–6.
23 Dickinson L, Boffito M, Back D et al. Population pharmacokinetics
of ritonavir-boosted atazanavir in HIV-infected patients and healthy
volunteers. J Antimicrob Chemother 2009; 63: 1233–43.
24 Gandhi M, Aweeka F, Greenblatt RM et al. Sex differences in pharmacokin-
etics and pharmacodynamics. Annu Rev Pharmacol Toxicol 2004; 44:
499–523.
25 Datz FL, Christian PE, Moore J. Gender-related differences in gastric
emptying. J Nucl Med 1987; 28: 1204–7.
26 Chen TS, Doong ML, Chang FY et al. Effects of sex steroid hormones on
gastric emptying and gastrointestinal transit in rats. Am J Physiol 1995;
268: G171–6.
27 Ribera E, Lopez RM, Diaz M et al. Steady-state pharmacokinetics of a
double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose
ritonavir in human immunodeficiency virus-infected adults. Antimicrob
Agents Chemother 2004; 48: 4256–62.
28 Umeh OC, Currier JS, Park JG et al. Sex differences in lopinavir and
ritonavir pharmacokinetics among HIV-infected women and men. J Clin
Pharmacol 2011; 51: 1665–73.
29 CDC. HIV/AIDS Surveillance Report, 2011; vol. 23. http://www.cdc.gov/
hiv/topics/surveillance/resources/reports.
30 Smith KY, Tierney C, Mollan K et al. Outcomes by sex following treat-
ment initiation with atazanavir plus ritonavir or efavirenz with abacavir/
lamivudine or tenofovir/emtricitabine. Clin Infect Dis 2014; 58: 555–63.
Venuto et al.
3310
